Nyxoah S.A. is a company.
Key people at Nyxoah S.A..
Nyxoah S.A. was founded by Robert Taub (Founder & Executive Chairman).
Nyxoah S.A. is a medical technology company that develops and commercializes the Genio® system, a battery-free, bilateral hypoglossal nerve stimulation (HGNS) therapy for treating moderate to severe Obstructive Sleep Apnea (OSA) in patients intolerant to CPAP.[1][2][3] It serves CPAP-failures and refusals, addressing OSA's health risks like cardiovascular disease and stroke by offering a minimally invasive, patient-centric alternative that stimulates the hypoglossal nerve to keep airways open during sleep.[1][2] With FDA approval secured in August 2025 and European commercialization underway, Nyxoah targets a $10 billion US HGNS market, leveraging proof-of-concept sales in Europe and planning a US launch to drive growth toward EBITDA profitability at a $300M revenue run-rate.[1][3]
Nyxoah S.A. was founded in 2009 by Robert Taub, who brought experience from medtech leadership and prior ventures like a Parkinson's pharmaceutical company that IPO'd on NASDAQ and sold to Mitsubishi-Tanabe.[3][4] The idea emerged from recognizing the need for innovative OSA treatments beyond CPAP, positioning Nyxoah as a pioneer in neurostimulation technology.[1][4] Pivotal moments include securing CE Mark under Europe's stringent MDR, European commercial traction proving the Genio® system's viability, and the landmark FDA approval in August 2025, unlocking the massive US market.[1][3]
Nyxoah stands out in the OSA therapy space through these key advantages:
Nyxoah rides the exploding demand for neurostimulation therapies in sleep medicine, fueled by OSA's prevalence as the world's most common sleep disorder linked to comorbidities like heart disease and stroke.[2] Timing is ideal post-FDA approval in 2025, aligning with payer recognition of HGNS in treatment algorithms and a firmly established subspecialty of device-forward ENT practices.[3] Market forces favor it: a $10B US opportunity with only 8% penetration, CPAP intolerance driving alternatives, and Nyxoah's blueprint to accelerate category growth via European proof-of-concept and US commercialization.[1][3] It influences the ecosystem by challenging incumbents, expanding access for underserved patients, and normalizing neurostimulation as a paradigm shift from masks to implants.[1][2]
Nyxoah is poised for rapid US expansion post-2025 FDA win, with a focused launch on top ENT accounts, strengthened referrals, and coverage via prior authorizations leading to profitability.[3] Trends like rising OSA awareness, reimbursement maturity, and medtech innovation in neurostimulation will propel it, potentially capturing significant share in the HGNS market.[3] Its influence may evolve from European pioneer to global leader, redefining sleep apnea care for millions—turning a overlooked condition into a solvable one through Genio®'s breakthrough therapy.[1][2]
Nyxoah S.A. was founded by Robert Taub (Founder & Executive Chairman).
Key people at Nyxoah S.A..
